TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nuformix Plc ( (GB:NFX) ) has shared an update.
Nuformix plc announced the results of its underwritten Open Offer, which closed on November 11, 2025. The offer was oversubscribed with valid acceptances for 465,813,047 shares, representing a take-up of approximately 408.5% of the available shares. The company will issue 114,040,535 shares, raising approximately £228,081 before expenses. This successful capital raise is expected to enhance Nuformix’s financial position and support its ongoing development efforts in the pharmaceutical sector.
Spark’s Take on GB:NFX Stock
According to Spark, TipRanks’ AI Analyst, GB:NFX is a Neutral.
Nuformix Plc’s overall stock score reflects severe financial challenges, including a lack of revenue and persistent losses. While recent positive corporate developments and technical momentum offer some optimism, they are overshadowed by significant financial instability and negative valuation metrics.
To see Spark’s full report on GB:NFX stock, click here.
More about Nuformix Plc
Nuformix plc is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing.
Average Trading Volume: 66,151,787
Technical Sentiment Signal: Buy
Current Market Cap: £7.08M
Learn more about NFX stock on TipRanks’ Stock Analysis page.